• SOPHiA GENETICS signed an MOU with Memorial Sloan Kettering Cancer Center to form a joint venture focused on precision oncology.
• Plan targets a “precision medicine hub” combining MSK clinical datasets with SOPHiA DDM to develop multimodal oncology tools for global deployment.
• MSK has sequenced more than 150,000 tumor samples since 2014; SOPHiA DDM has analyzed more than 2.5 million cases since 2014.
• Hub would also support biopharma work on companion diagnostics, clinical algorithms, evidence generation.
• SOPHiA previously commercialized MSK-IMPACT and MSK-ACCESS assays via its platform in 35 countries.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief on June 04, 2026, and is solely responsible for the information contained therein.